Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial abstract · §2

REDEFINE-4 — design and population

Design, allocation, arms and the population enrolled.

Document identifier
CEI-TR-0051/2
Series
Trial abstract
Version
3.1
Published
14 Feb 2026
Last reviewed
14 May 2026
Next review
14 May 2028
Identifier
10.71829/cei.trial.51
Certainty
Not rated
Cycle
2026 Q1
Phase
Phase 3
Status
Ongoing

§2Design and population

§2.1Design and allocation

Design class
Randomised, double-blind, active-controlled, parallel-group
Masking
Double-blind (participant and investigator)
Arms
2
Allocation
Randomised between the intervention and its comparator
Endpoint adjudication
Not applicable to the primary endpoint of this design
Data monitoring
As specified in the protocol

§2.2Arms

Table 2. Randomised arms. Illustrative: arm-level allocations are reconstructed by the Institute from the design class and the randomised total where the published report does not state them.

ArmAllocatedShareDescription
CagriSema (cagrilintide with semaglutide)Intervention at the dose reached after titration
Active comparatorComparator agent at the dose specified in the protocol
The randomised total is not recorded by the Institute and arm-level figures are therefore not presented.

§2.3Population

Indication. Obesity and overweight in adults

Excess adiposity sufficient to impair health, operationalised in the pivotal incretin programmes as a body-mass index of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity.

Geographic footprint. Hungary.

§2.4Eligibility as the Institute reads it

  • Included. Excess adiposity sufficient to impair health, operationalised in the pivotal incretin programmes as a body-mass index of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity.
  • Excluded. Participants for whom the intervention is contraindicated, including as for each component. Exclusion criteria narrow the population to which the estimate applies and are the principal source of indirectness where a trial estimate is applied to ordinary practice.
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.